Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. Kelemen et al. find that ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.